Skip to main content

Table 3 Pharmacokinetics of erlotinib after single-dose administration in combination with motesanib

From: Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study

   AUC0—24   Cmax
Dose Cohort n GLSM Ratio
Week 3: Week 2a
(90% CI)
n GLSM Ratio
Week 3: Week 2a
(90% CI)
50 mg motesanib QD + 100 mg erlotinib QD + gemcitabine 7 0.49 (0.25-0.96) 7 0.65 (0.39-1.08)
100 mg motesanib QD + 100 mg erlotinib QD + gemcitabine 7 0.53 (0.25-1.11) 8 0.82 (0.49-1.37)
125 mg motesanib QD + 100 mg erlotinib QD + gemcitabine 9 0.91 (0.48-1.73) 10 0.73 (0.48-1.09)
75 mg motesanib BID + 100 mg erlotinib QD + gemcitabine 9 0.52 (0.37-0.74) 9 0.75 (0.54-1.05)
100 mg motesanib QD + 150 mg erlotinib QD 7 0.46 (0.34-0.60) 7 0.59 (0.41-0.84)
125 mg motesanib QD + 150 mg erlotinib QD 7 0.46 (0.19-1.13) 7 0.61 (0.50-0.73)
  1. AUC0—24 = area under the curve from time 0-24 h; BID = twice daily; Cmax = peak plasma concentration; CI = confidence interval; GLSM = geometric least squares means; QD = once daily
  2. aWeek 3, erlotinib plus motesanib treatment; week 2, erlotinib treatment only.